The Impact of N-acetylcysteine on Major Depression: Qualitative Observation and Mixed Methods Analysis of Participant Change during a 12-week Randomised Controlled Trial
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: N-acetylcysteine (NAC) is a novel therapeutic agent with multiple mechanisms of action in the central nervous system and a favourable side effect profile. Clinical evidence indicates that adjunctive NAC may reduce the severity of depressive symptoms in individuals with major depressive disorder (MDD). Methods: A 12-week randomised controlled trial of 2,000 mg/day adjunctive NAC for MDD found no significant improvement at the primary endpoint (week 12) but did see improvements at the post-discontinuation interview (week 16). Within the context of patient-centered treatment, mixed-methods qualitative analysis was also included to explore factors that may determine individual responses to adjunctive NAC treatment. These data were drawn, under blinded conditions, from clinician notes recorded in the case report form. Using the DSM-5 symptom profile for MDD as the initial framework, themes were developed and explored. Frequencies were compared between placebo and NAC groups. Results: Per protocol analysis of individual themes across the six interviews revealed group differences in favour of NAC for overall depressive affect, optimism, relationships and reduced functional impairment. Conclusion: This study provides further evidence for the utility of the mixed methods approach complimenting the primary findings using traditional quantitative analyses, as well as being able to capture additional, often more subtle, evidence of individual symptom-level change that reflects improvement in functional abilities in response to NAC supplementation. The use of mixed methods to explore outcomes from psychiatric studies should be considered in future to work towards improved patient-centred care and both confirm quantitative findings and generate novel hypotheses.
Abstract
Objective: N-acetylcysteine (NAC) is a novel therapeutic agent with multiple mechanisms of action in the central nervous system and a favourable side effect profile. Clinical evidence indicates that adjunctive NAC may reduce the severity of depressive symptoms in individuals with major depressive disorder (MDD). Methods: A 12-week randomised controlled trial of 2,000 mg/day adjunctive NAC for MDD found no significant improvement at the primary endpoint (week 12) but did see improvements at the post-discontinuation interview (week 16). Within the context of patient-centered treatment, mixed-methods qualitative analysis was also included to explore factors that may determine individual responses to adjunctive NAC treatment. These data were drawn, under blinded conditions, from clinician notes recorded in the case report form. Using the DSM-5 symptom profile for MDD as the initial framework, themes were developed and explored. Frequencies were compared between placebo and NAC groups. Results: Per protocol analysis of individual themes across the six interviews revealed group differences in favour of NAC for overall depressive affect, optimism, relationships and reduced functional impairment. Conclusion: This study provides further evidence for the utility of the mixed methods approach complimenting the primary findings using traditional quantitative analyses, as well as being able to capture additional, often more subtle, evidence of individual symptom-level change that reflects improvement in functional abilities in response to NAC supplementation. The use of mixed methods to explore outcomes from psychiatric studies should be considered in future to work towards improved patient-centred care and both confirm quantitative findings and generate novel hypotheses.
참고문헌 (32)
- Kessler RC, "Prevalence, persistence, and sociodemographic correlates of DSM-IV disorders in the National Comorbidity Survey Replication Adolescent Supplement", Arch Gen Psychiatry, 69, pp.372~380 (2012)
- GBD 2017 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017 : a systematic analysis for the Global Burden of Disease Study 2017", Lancet, 392, pp.1789~1858 (2018)
- World Health Organization, "Global burden of mental disorders and the need for a comprehensive, coordinated response from health and social sectors at the country level: report by the Secretariat", World Health Organization, ~ (2021)
- Malhi GS, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders", Aust N Z J Psychiatry, 49, pp.1087~1206 (2015)
- Trivedi MH, "Medication augmentation after the failure of SSRIs for depression", N Engl J Med, 354, pp.1243~1252 (2006)
- Vöhringer PA, "Solving the antidepressant efficacy question : effect sizes in major depressive disorder", Clin Ther, 33, pp.B49~ (2011)
- Baldwin DS, "Impact of antidepressant drugs on sexual function and satisfaction", CNS Drugs, 29, pp.905~913 (2015)
- Masand PS, "Long-term side effects of newer-generation antidepressants : SSRIS, venlafaxine, nefazodone, bupropion, and mirtazapine", Ann Clin Psychiatry, 14, pp.175~182 (2002)
- Serretti A, "Antidepressants and body weight : a comprehensive review and meta-analysis", J Clin Psychiatry, 71, pp.1259~1272 (2010)
- Keller MB, "Optimizing outcomes in depression : focus on antidepressant compliance", Int Clin Psychopharmacol, 17, pp.265~271 (2002)
- MacDonald TM, "Antidepressant drug use in primary care : a record linkage study in Tayside, Scotland", BMJ, 313, pp.860~861 (1996)
- Maddox JC, "The compliance with antidepressants in general practice", J Psychopharmacol, 8, pp.48~52 (1994)
- Samuni Y, "The chemistry and biological activities of N-acetylcysteine", Biochim Biophys Acta, 1830, pp.4117~4129 (2013)
- Berk M, "The promise of N-acetylcysteine in neuropsychiatry", Trends Pharmacol Sci, 34, pp.167~177 (2013)
- De Rosa SC, "N-acetylcysteine replenishes glutathione in HIV infection", Eur J Clin Invest, 30, pp.915~929 (2000)
- Fernandes BS, "N-Acetylcysteine in depressive symptoms and functionality : a systematic review and meta-analysis", J Clin Psychiatry, 77, pp.e457~ (2016)
- Berk M, "The efficacy of adjunctive N-acetylcysteine in major depressive disorder : a double-blind, randomized, placebocontrolled trial", J Clin Psychiatry, 75, pp.628~636 (2014)
- Dean OM, "Does N-acetylcysteine improve behaviour in children with autism? : a mixed-methods analysis of the effects of N-acetylcysteine", J Intellect Dev Disabil, 44, pp.474~480 (2019)
- Berk M, "A randomised controlled trial of a mitochondrial therapeutic target for bipolar depression : mitochondrial agents, N-acetylcysteine, and placebo", BMC Med, 17, pp.18~ (2019)
- McKetin R, "N-acetylcysteine(NAC)for methamphetamine dependence : a randomised controlled trial", EClinicalMedicine, 38, pp.101005~ (2021)
- Montgomery SA, "A new depression scale designed to be sensitive to change", Br J Psychiatry, 134, pp.382~389 (1979)
- Hasebe K, "Adjunctive N-acetylcysteine in depression : exploration of interleukin-6, C-reactive protein and brain-derived neurotrophic factor", Acta Neuropsychiatr, 29, pp.337~346 (2017)
- Berk M, "Qualitative methods in early-phase drug trials : broadening the scope of data and methods from an RCT of N-acetylcysteine in schizophrenia", J Clin Psychiatry, 72, pp.909~913 (2011)
- Berk M, "Clinical trial design challenges in mood disorders", pp.59~74 (2015), Elsevier Inc
- Samantha E. Russell, "Mixed Methods Thematic Analysis of a Randomised Controlled Trial of Adjunctive Mitochondrial Agents for Bipolar Depression", Clinical Psychopharmacology and Neuroscience, 20(2), pp.300~310 (2022), 대한정신약물학회[DOI]
- World Medical Association, "World Medical Association Declaration of Helsinki : ethical principles for medical research involving human subjects", JAMA, 310, pp.2191~2194 (2013)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5" (2013), American Psychiatric Publishing
- "NVivo (version 11)" (2019)[URL]
- Miles MB, "Qualitative data analysis:a methods sourcebook" (2014), Sage Publications Ltd
- Saldaña J, "The coding manual for qualitative researchers" (2009), Sage Publications Ltd
- IBM Corp, "Released 2019. IBM SPSS statistics for windows, version 26.0", IBM Corp, ~ (2019)
- Lee TM, "Effectiveness of N-acetylcysteine in autism spectrum disorders : a metaanalysis of randomized controlled trials", Aust N Z J Psychiatry, 55, pp.196~206 (2021)